Prognosis group¶ | Definition | Regimen | DoseΔ | Schedule |
Low risk | ||||
Subset A Excellent prognosis (>85% EFS) | Embryonal and alveolar fusion-negative tumors:
| VA per subset A regimen of D9602 × 15 cycles (45 weeks)[1] | ||
Vincristine | 1.5 mg/m2 (max 2 mg) | Weekly during weeks 0 to 8, 12 to 20, 24 to 32, and 36 to 44 | ||
Dactinomycin | 0.045 mg/kg (max 2.5 mg) | Every 3 weeks during weeks 0 through 45◊ | ||
OR | ||||
VAC/VA per subset A regimen of ARST0331 × 8 cycles (24 weeks)§[2] | ||||
Vincristine | 1.5 mg/m2 (max 2 mg) | Weekly during weeks 1 to 9 and 13 to 21 | ||
Dactinomycin | 0.045 mg/kg (max 2.5 mg) | Every 3 weeks during weeks 1 to 22◊ | ||
Cyclophosphamide | 1200 mg/m2 with mesna and as-needed hematopoietic growth factor support | Every 3 weeks during weeks 1 to 10 for a total of 4 doses | ||
Subset B Very good prognosis (70 to 85% EFS) | Embryonal and alveolar fusion-negative tumors:
| VAC × 14 cycles (40 weeks)¥[3] | ||
Vincristine | 1.5 mg/m2 (max 2 mg) | Weekly during weeks 1 to 13, 16, 19 to 25, 28, 31, 34 to 37, and 40 | ||
Dactinomycin | 0.045 mg/kg (max 2.5 mg) | Every 3 weeks during weeks 1 through 40◊ | ||
Cyclophosphamide | 2200 mg/m2 with mesna and hematopoietic growth factor support | Every 3 weeks during weeks 1 through 40 | ||
Intermediate risk | ||||
Good prognosis (50 to 70% EFS) | Embryonal and alveolar fusion-negative tumors:
| VAC × 14 cycles (40 weeks)¥[3] | ||
Vincristine | 1.5 mg/m2 (max 2 mg) | Weekly during weeks 1 to 13, 16, 19 to 25, 28, 31, 34 to 37, and 40 | ||
Dactinomycin | 0.045 mg/kg (max 2.5 mg) | Every 3 weeks during weeks 1 through 40◊ | ||
Cyclophosphamide | 2200 mg/m2 with mesna and hematopoietic growth factor support | Every 3 weeks during weeks 1 through 40 | ||
High risk | ||||
Poor prognosis (<30% EFS) | Embryonal and alveolar fusion-negative tumors:
| VAC × 14 cycles (40 weeks)‡[4] | ||
Vincristine | 1.5 mg/m2 (max 2 mg) | Weekly during weeks 1 to 13, 19 to 25, and 31 to 37 | ||
Dactinomycin | 0.045 mg/kg (max 2.5 mg) | Every 3 weeks during weeks 1 through 40◊ | ||
Cyclophosphamide | 1200 mg/m2 with mesna and hematopoietic growth factor support | Every 3 weeks during weeks 1 through 40 |